Analysis of immunological markers associated with pregnancy and HIV-1 infection: Relevance in perinatal transmission in HIV-1-infected pregnant women with low plasma viral load

American Journal of Reproductive Immunology

Volumn 60, Issue 3, 2008, Pages 264-273

  Sachdeva, Naresh ^a   Oshima, Kyoko ^b   Cotter, Amanda ^a   Ashman, Margarita ^a   Davila, Leonardo ^a   Okazaki, Takayuki ^b   Inaba, Noriyuki ^b   Asthana, Deshratn ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Dokkyo Medical University   (Japan)

Author keywords

Activated T cells; CD8 T cells; Cytokines; HIV 1; Myeloid related protein 8; Perinatal HIV 1 transmission; Pregnant women; Secretory leukocyte peptidase inhibitor

Indexed keywords

CALGRANULIN; CD38 ANTIGEN; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; HLA DR ANTIGEN; IMMUNOLOGIC FACTOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CESAREAN SECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOLOGICAL PARAMETERS; INFECTION RISK; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PLACENTAL TRANSFER; PREGNANCY; PREGNANT WOMAN; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; T LYMPHOCYTE SUBPOPULATION; UTERINE CERVIX CYTOLOGY; VAGINAL DELIVERY; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTIGENS, CD28; ANTIGENS, CD38; ANTIGENS, CD95; ATP-BINDING CASSETTE TRANSPORTERS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 50149089060     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2008.00627.x     Document Type: Article

References (25)

1. Luzuriaga K, Sullivan JL: Prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2005; 40:466-467.
2. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W: Women and Infants' Transmission Study Group: Combination anti-retroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494.
3. Plaeger S, Bermudez S, Mikyas Y, Harawa N, Dickover R, Mark D, Dillon M, Bryson YJ, Boyer PJ, Sinsheimer JS: Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants. J Infect Dis 1999; 179:1388-1394.
4. + noncytotoxic antiviral activity. AIDS Res Hum Retroviruses 1999; 15:665-670.
5. Mikyas Y, Aziz N, Harawa N, Gorre M, Neagos N, Nogueira M, Wafer D, Dillon M, Boyer PJ, Bryson YJ, Plaeger S: Immunologic activation during pregnancy: Serial measurement of lymphocyte phenotype and serum activation molecules in HIV-infected and uninfected women. J Reprod Immunol 1997; 33:157-170.
6. Abrams ET, Milner DA Jr, Kwiek J, Mwapasa V, Kamwendo DD, Zeng D, Tadesse E, Lema VM, Molyneux ME, Rogerson SJ, Meshnick SR: Risk factors and mechanisms of preterm delivery in Malawi. Am J Reprod Immunol 2004; 52:174-183.
7. Lambert JS, Moye J Jr, Plaeger SF, Stiehm ER, Bethel J, Mofenson LM, Mathieson B, Kagan J, Rosenblatt H, Paxton H, Suter H, Landay A: Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol 2005; 12:622-631.
8. Faye A, Pornprasert S, Mary JY, Dolcini G, Derrien M, Barré-Sinoussi F, Chaouat G, Menu E, for the ANRS 1267 Study Team and the HIV-1 PMTCT-PlaNet: Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France. Clin Exp Immunol 2007; 149:430-439.
9. Kedzierska K, CIowe SM: Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001; 12:133-150.
10. Alfano M, Poli G: Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol 2005; 42:161-182.
11. Sutton MY, Holland B, Denny TN, Garcia A, Garcia Z, Stein D, Bardeguez AD: Effect of pregnancy and human immunodeficiency virus infection on intracellular interleukin-2 production patterns. Clin Diagn Lab Immunol 2004; 11:780-785.
12. Fiore S, Newell ML, Trabattoni D, Thorne C, Gray L, Savasi V, Tibaldi C, Ferrazzi E, Clerici M: Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70:143-150.
13. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, Challacombe SJ: Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006; 13:1111-1118.
14. Gruetter M, Fendrich G, Huber R, Bode W: The 2.5A X-ray crystal structure of the acid-stable protease inhibitor from human mucous secretions analyzed in its complex with bovine alpha-chymotrypsin. EMBO J 1988; 7:345-352.
15. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity be secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:1141-1149.
16. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C, Harms E, Sorg C, Roth J: Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful makers for monitoring disease activity in paruciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43:628-637.
17. Hashemi FB, Mollenhauer J, Madsen LD, Sha BE, Nacken W, Moyer MB, Sorg C, Spear GT: Myeloid-related protein (MRP)-8 from cervico vaginal secretions activates HIV replication. AIDS 2001; 15:441-449.
18. Sachdeva N, Yoon HS, Oshima K, Garcia D, Goodkin K, Asthana D: Biochip-array based analysis of plasma cytokines in HIV patients with immunological and virological discordance. Scand J Immunol 2007; 6:549-554.
19. Pitt J, Brambilla D, Reichelderfer P, Landay A, McIntosh K, Burns D, Hillyer GV, Mendez H, Fowler MG: Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175:567-575.
20. Ascherl G, Hohenadl C, Schatz O, Shumay E, Bogner J, Eckhart L, Tschachler E, Monini P, Ensoli B, Stürzl M: Detection of increased VEGF serum concentrations in HIV-1-infected patients: Implications for AIDS-associated vasculopathy. Blood 1999; 93:4232-4241.
21. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183:653-656.
22. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hrdegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200:1337-1346.
23. Draper D, Donohoe W, Mortimer L, Heine RP: Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis 1998; 178:815-819.
24. Strasser F, Gowland PL, Ruef C: Elevated serum macrophage inhibitory factor-related protein (MRP) 8/14 levels in advanced HIV infection and during disease exacerbation. J Acquir Immune Defic Syndr 1997; 16:230.
25. + T lymphocytes. J Immunol 2002; 169:3307-3313.